Prezista label
Interaction Color Code
Clinical Bottom Line
Do not coadminister: Increased levels of grazoprevir
Drug 1
Drug 1 dose
800 mg once daily
Drug 1 effect
No significant change
Drug 2
Drug 2 dose
50 / 100 mg once daily
Drug 2 effect
Elbasvir AUC increase 66%; Grazoprevir AUC increase 7.5 fold
Clinical Effects
Potential for increased risk of ALT elevations due to a significant increase in grazoprevir plasma concentrations caused by OATP1B1 / 3 inhibition
Management
Contraindicated. Use alternative agents.
Import ID
920
